Bristol Myers and Microsoft Collaborate on AI-Driven Lung Cancer Detection
Bristol Myers Squibb announced on Tuesday, January 20, 2026, a groundbreaking collaboration with Microsoft to expedite the early detection of lung cancer through AI-powered radiology technology. The partnership will leverage U.S. FDA-cleared radiology AI algorithms via Microsoft’s Precision Imaging Network, a platform currently utilized by over 80 percent of hospitals in the United States.
The AI tools will scrutinize X-ray and CT images, assisting clinicians in identifying elusive lung nodules and potentially pinpointing patients at earlier disease stages. The system’s primary goal is to aid radiologists in their daily workflow, decrease clinical workload, and facilitate the triage of patients for appropriate care.
A fundamental objective of this collaboration is to broaden access to early detection in medically underserved communities. This includes rural hospitals and community clinics across the United States. The partnership signifies a growing trend of pharmaceutical companies harnessing the power of artificial intelligence to expedite research and development. A testament to this trend is AstraZeneca’s recent acquisition of Boston-based Modella AI for similar objectives.
Source: BNN Bloomberg